Why the study?
Do endogenous opioid mechanisms mediate the decompensatory haemodynamic response to acute blood loss?
Do endogenous opioid mechanisms mediate the decompensatory haemodynamic response to acute blood loss?
The decompensatory phase of acute blood loss in animals is mediated by an endogenous opioid mechanism triggered by the heart, offering potential new therapeutic targets if confirmed in humans.
Should not change management of acute blood loss; leaves open opioid modulation as a translational research target.
Information has come forward recently from several sources which provides new insights into the mechanisms that underlie the haemodynamic responses to acute blood loss. In unanaesthetised animals and human volunteers there are two distinct phases to these responses. At first, the engagement of baroreflexes results in a progressive rise in sympathetic vasoconstrictor drive and peripheral resistance, and the maintenance of arterial blood pressure at a near-normal level. When about one-third of blood volume has been lost, reflex sympathetic drive is switched off, and peripheral resistance and blood pressure fall abruptly to low levels despite a burst of vasopressin release. Research in conscious animals has now shown that the onset of this decompensatory phase is triggered by a signal from the heart, which activates an endogenous opioid mechanism in the brain. Activation of this mechanism can be prevented by administering a selective delta-receptor antagonist, or selective mu-receptor agonists (including alfentanil). It has not yet been established that this endogenous opioid mechanism is responsible for the decompensatory phase of acute blood loss in man, nor that it can be prevented or reversed by selective opioid agonists or antagonists.
No takes yet. Share an insight, caveat, or question.
Leeuwen et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: